The site of the awarding ceremony for Yangtze River Pharmaceutical Group's first Major
                                           Contribution Prize for Innovation Research and Development Programs

            
                                  Lu Xianfeng, the Company's General Manager's Assistant, presents awards to
                                                                     Dizozine Tianjin Pharmaceutical Institute

            
            Zheng Lu, the Company’s General Manager's Assistant, presents award to Professor Gao Pengxiang

            
                                    Xu Jingren, the Company's Chairman, addresses the awarding ceremony

To encourage independent innovation and improve the level of research and development, Yangtze River Pharmaceutical Group held the awarding ceremony for Major Contribution Prize for Innovation Research and Development Programs, where the Company gave 650,000 yuan as reward to the contributors or their descendants of Dizozine program, Bailemian program and Weisu granule, and Bilingweitong granules in the Company's headquarters on April 13. Among the rewards, 200,000 yuan was given to the Tianjin Medicine Institute for the Dizozine program, 200,000 yuan was given to Professor Gao Pengxiang for the Bailemian program, and 250,000 yuan was given to Dong Jianhua's descendants for the Weisu granule and Bilingweitong granules program. Yangtze River Pharmaceutical Group's Chairman Xu Jingren presented the award to the researchers.

Yangtze River Pharmaceutical Group has long been devoting to the development of modern Chinese medicine and innovative medicines. 20 years ago, Yangtze River Pharmaceutical Group occupied its position in traditional Chinese medicine market with its new product Weisu granules. Weisu granules had since then helped countless patients, bringing hope to them and also charting a course of modernization for Yangtze River Pharmaceutical Group's Chinese medicine.

On its path from the King of Banlangen to today's King of Weisu, Yangtze River Pharmaceutical Group has been seeking progress and making new contribution throughout the 40 years. Yangtze River Pharmaceutical Group searched for the renowned traditional Chinese doctors, exploring the prescription of traditional Chinese medicine, and developed Weisu granules, Bailemian capsules, Lanqin oral preparation, Shuanghua Lily tablets, etc., hitting the market as the pioneer and making itself No.1 in the Top 100 Pharmaceutical Companies in China.

Weisu granule is the first Chinese product with independent intellectual property right to be made by Yangtze River Pharmaceutical Group. Xu Jingren travelled to distant places to find the famous prescription of traditional Chinese medicine. And, through hard efforts, Yangtze River Pharmaceutical Group eventually found the proved recipe for gastric problems held by Professor Dong Jianhua, who was well-known as the Master of Traditional Chinese Medicine. Xu Jingren travelled north to visit Dong Jianhua for three times, persuaded the professor with his ambition to rejuvenate the national pharmaceutical industry, and he eventually obtained the proved recipe for gastric problems. After obtaining the recipe, Yangtze River Pharmaceutical Group came up with a set of development plans and embarked on the expedition of producing Weisu granule. The researchers in the development department immersed themselves on the lab and piles of materials, searched for data and tested the ingredients. Day after day and year after year, the documents of materials on the efficiency of the medicines were mounting. Eventually, in 1993, the first state-class Chinese medicine new product Weisu granule was launched since the new drug police was promulgated in 1993.

As a specific medicine for the treating epigastric pain, Weisu was well received by the patients and hospitals as soon as it was launched to the market with its modern craftsmanship, unique ingredients and effectiveness. In 1997, Weisu granules won the International Golden Prize in the Global Chinese Pharmaceutical Exchange Conference in Los Angeles, USA. In 1999, recommended by the China Council for Promotion of International Trade, Weisu was listed as a recommended product to EU market and obtained a passport to EU market, having passed the review of French Scien-Tech Quality Supervision Evaluation Committee. The French Scien-Tech Quality Supervision Evaluation Committee also awarded Weisu with a certificate on High Quality Scientific and Technological Product. In the following years, Weis won an array of titles such as Recommended Medicines by Doctors in China, Renowned Traditional Chinese Medicine Brand in China, protected Traditional Chinese medicine, No.1 Satisfactory Product in Chinese Market, etc. Today, as a knock-out product, Weisu's sale has reached six billion, being the champion of gastric medicine in China.

Professor Gao Pengxiang, born to a renowned family known for its generational expertise of traditional Chinese medicine, held that the reasons for insomnia were from the external sense and internal injury. He came up with new approaches such as keeping cool and nourishing yin, calming down temper and concentrating, relieving stress in livers, promoting the production of body fluid, smoothing and enlivening blood circulation. In response to the new findings during the course of research, Professor Gao Pengxiang used the abundant medical resources in Changbai Mountain, selected lily, acanthopanax (Ciwujia), albizia flower (Hehuanhua), rehmannia among other Chinese medicine ingredients conducive to nourishing yin and conducted research and experiment to treat insomnia. YRPG followed Professor Gao's recipe and developed the Bailemian capsule, which was pure traditional Chinese medicine preparation to cure insomnia. Since its debut, the medicine has helped millions of victims of insomnia to rid of the over-reliance on western sedatives, improved the patients' life quality as a green and safe solution to insomnia caused by fire access from yin deficiency.

In the preparation craftsmanship of Bailemian capsules, YRPG used the complex macro porous adsorption resin purification technology, overcame the problem of monotonous ingredient of macro porous adsorption resin. The successful application of the technology helped set up an example in the craftsmanship technical engineering in traditional Chinese medicine and obviously improved the technical standards and quality of modern Chinese medicine. After adopting new craftsmanship and technology, Bailemian witnessed a significant improvement in its product quality and was listed as the National Key and New Product Plan and Jiangsu Key Technological Innovation Program. It won the special support from state and provincial level, won the third prize in Jiangsu Scientific and Technological Progress, Jiangsu Hi-tech Product, Jiangsu Excellent Invention Patent, Jiangsu Product of Independent Innovation, etc.

In 2009, through collaboration with Tianjin Medicine Institute, YRPG developed its national type 2 medicine, Dizocine injection. As an effective opioid pain-relieving medicine, this medicine is durable and safe to users. It also had little addictive effect on its users. Dizocine won wide acclamation from both clinical doctors and the market, including prizes such as Jiangsu Famous Trademark, Jiangsu Famous Brand and Jiangsu Science and Technology Progress Prize. As the data from National Medicine Adverse Effect of Medicine showed, there has been no severe adverse effect from the use of Dizocine. Chinese Medical Society's data of sampling hospitals also indicated that Dizocine was No.1 in the market of opioid pain-relieving medicine.

Xu Jingren, the Chairman, said that the awarding for major contributions to innovative research and development was a respect and reward to the contributors and developers of the results, and would further enhance wider and more extensive research and development centers to work with YRPG, to complement each other and to develop new medicines with high effectiveness, high quality and high technological content, bestowing more well-being to the general public.